Anti-Human CD19 (Tafasitamab)

Anti-Human CD19 (Tafasitamab)

Product No.: LT3100

- -
- -
Product No.LT3100
Clone
MOR-208
Target
CD19
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Tafasitamab,MOR-00208,MOR-208,CD19, 1422527-84-1
Isotype
Human IgG1κ
Applications
ELISA
,
FA
,
FC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Recommended Isotype Controls
Immunogen
Human CD19
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Additional Applications Reported In Literature ?
ELISA
WB
IP
FA
FC
IF
IF Microscopy
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Tafasitamab activity is directed against human CD19.
Background
CD19 is a B cell surface glycoprotein that enhances B cell receptor signaling and tumor cell proliferation 1. CD19 is an attractive immunotherapy target for cancers of lymphoid origin due to its early and persistent expression throughout B cell maturation 2.

Tafasitamab is a humanized anti-CD19 monoclonal antibody developed by MorphoSys AG under a license from Xencor for the treatment of B cell malignancies 1. The chimeric antibody was engineered by combining the variable region genes of mouse anti-CD19 antibody (clone 4G7) with human light chain κ and heavy chain constant regions 1,2. Light and heavy chain constructs were co-transfected into 293E cells and antibodies were purified using protein A chromatography 2. Additionally, the Fv of 4G7 was humanized, affinity-matured using library design automation, and substitutions S239D/I332E were introduced to increase Fcγ receptor affinity to human 2, mouse 2, and cynomolgus monkey 3 FcγRs, with FcγRIIIa affinity being particularly enhanced 2.

Tafasitamab mediates B cell lysis via apoptosis and immune effector mechanisms including antibody-dependent cellular cytotoxicity (ADCC) 2,4 and antibody-dependent cellular phagocytosis 2. Tafasitamab also increases antiproliferative activity and inhibits lymphoma growth in mouse xenograft models. ADCC is mediated by natural killer cells 5 through a granzyme B-dependent mechanism that is further enhanced by lenalidomide 6,7.

Tafasitamab is also known as XmAb5574 1.
Antigen Distribution
CD19 is a surface antigen present on all B cells (healthy and malignant) except hematopoietic stem cells and plasma cells; it is highly conserved in B-cell malignancies.
Ligand/Receptor
CD21, CD81
NCBI Gene Bank ID
UniProt.org
Research Area
Biosimilars
.
Immuno-Oncology
.
Immunology
.
Oncology

References & Citations

1. Hoy SM. Tafasitamab: First Approval. Drugs. 80(16):1731-1737. 2020.
2. Horton HM, Bernett MJ, Pong E, et al. Cancer Res. 68(19):8049-8057. 2008.
3. Zalevsky J, Leung IW, Karki S, et al. Blood. 113(16):3735-3743. 2009.
4. Rafiq S, Cheney C, Mo X, et al. Leukemia. 26(7):1720-1722. 2012.
5. Chan WK, Kung Sutherland M, Li Y, et al. Clin Cancer Res. 18(22):6296-6305. 2012.
6. Awan FT, Lapalombella R, Trotta R, et al. Blood. 115(6):1204-1213. 2010.
7. Kellner C, Zhukovsky EA, Pötzke A, et al. Leukemia. 27(7):1595-1598. 2013.
8. Woyach JA, Awan F, Flinn IW, et al. Blood. 124(24):3553-3560. 2014.
Indirect Elisa Protocol
FA
Flow Cytometry
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Formats Available

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.